SHARE THIS ARTICLE:

Hygromycin A Headed for Human Trials in Australia

March 9, 2024

Northeastern Global News (Cynthia McCormick Hibbert, 02.28.24) published “Experimental antibiotic treatment for Lyme heads for human safety trials.” Human safety trials are scheduled to begin for hygromycin A this spring in Australia. Hygromycin A is a novel antibiotic treatment for Lyme disease developed by Northeastern professor Kim Lewis. So far, hygromycin A has been found to clear Lyme spirochete infections in mice without any toxicity to animals.

This long overlooked antibiotic specifically targets spirochetes, leaving the microbiome of the gut intact unlike the broad spectrum antibiotic, doxycycline, typically used to treat Lyme disease. If successful in human safety trials, hygromycin A will then be tested for effectiveness in clearing Lyme spirochete infection from patients with acute disease. There is hope that this drug will also benefit chronic Lyme patients in clearing persistent disease. Results for the human safety trials of hygromycin A are expected by fall.

LDA Note: Kim Lewis spoke on Hygromycin A during his talk on “Developing therapies for Lyme disease” at The Lyme Disease Association/Columbia University Vagelos College of Physicians & Surgeons Virtual Conference in 2021. See video below.

For More Information:

Read the Northeastern Global News Article

Watch LDA-Columbia 2021 Lyme Conference Videos